NICE published the Clinical Melanoma Guideline in July 2015. This Guideline is directed at secondary and tertiary care (hospital treatment) in the UK and considers the role of treatments such as sentinel node biopsy.
This is a link to the guideline http://www.nice.org.uk/guidance/ng14
The Guideline addressed the role of sentinel node biopsy and regular body scans after diagnosis, among other issues. The decision was made to develop information for melanoma patients about the advantages and disadvantages of sentinel node biopsy and regular imaging. This information was developed in conjunction with Option Grid and was published in December 2015. The grids can be obtained direct from the Option Grid web page but are also provided in the Option Grid post.
NICE asked Professor Julia Newton-Bishop to discuss why vitamin D was considered by the Clinical Melanoma Guideline and this is the link to her podcast
We have updated the plain language summaries of GenoMEL research in the Information for Patients section. More to follow!
The Journal of the National Cancer Institute has published a new GenoMEL paper examining the role of chromosomal telomere length in melanoma. The research involved creating a score representing genetically determined telomere length, based on all the established telomere associated genes and found that this score correlated with melanoma risk.
In an associated press release author Dr Mark Iles summarised the research, “Telomeres have been described as being like the plastic tips on shoelaces that protect the shoelace from fraying, just as telomeres protect chromosomes from degrading or fusing to one another. For the first time, we have established that the genes controlling the length of these telomeres play a part in the risk of developing melanoma.”
Telomeres are akin to shoe lace caps (aglets)
The International Journal of Cancer has published a new GenoMEL paper entitled, “Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions“. It reports the results of examining genetic data from over 5,000 individuals with melanoma and over 7,000 individuals without melanoma.
The consortium’s coordinator, Prof. Julia Newton Bishop, has been elected to theFellowship of the Academy of Medical Sciences. Academy Fellows are elected for excellence in medical research, innovative application of scientific knowledge or conspicuous service to healthcare. This prestigious award is recognition of Julia’s contribution to understanding melanoma genetics.